Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Neurochem Res ; 45(11): 2732-2748, 2020 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-32910302

RESUMO

Promoting remyelination in multiple sclerosis is important to prevent axon degeneration, given the lack of curative treatment. Although some growth factors improve this repair, unspecific delivery to cells and potential side effects limit their therapeutic use. Thus, NFL-TBS.40-63 peptide (NFL)-known to enter specifically myelinating oligodendrocytes (OL)-was used to vectorize 100 nm diameter lipid nanoparticles (LNC), and the ability of NFL-LNC to specifically target OL from newborn rat brain was assessed in vitro. Specific uptake of DiD-labeled NFL-LNC by OL characterized by CNP and myelin basic protein was observed by confocal microscopy, as well as DiD colocalization with NFL and with Rab5-a marker of early endosomes. Unvectorized LNC did not significantly penetrate OL and there was no uptake of NFL-LNC by astrocytes. Canonical maturation of OL which extended compacted myelin-like membranes was observed by transmission electron microscopy in cells grown up to 9 days with NFL-LNC. Endocytosis of NFL-LNC appeared to depend on several pathways, as demonstrated by inhibitors. In addition, vectorized NFL-LNC adsorbed on neurotrophin-3 (NT-3) potentiated the proremyelinating effects of NT-3 after demyelination by lysophosphatidyl choline, allowing noticeably decreasing NT-3 concentration. Our results if they were confirmed in vivo suggest that NFL-vectorized LNC appear safe and could be considered as putative carriers for specific drug delivery to OL in order to increase remyelination.


Assuntos
Nanopartículas/química , Proteínas de Neurofilamentos/farmacologia , Fármacos Neuroprotetores/farmacologia , Neurotrofina 3/metabolismo , Oligodendroglia/efeitos dos fármacos , Fragmentos de Peptídeos/farmacologia , Remielinização/efeitos dos fármacos , Sequência de Aminoácidos , Animais , Animais Recém-Nascidos , Astrócitos/efeitos dos fármacos , Diferenciação Celular/efeitos dos fármacos , Portadores de Fármacos/química , Endocitose , Humanos , Lipídeos/química , Lisofosfatidilcolinas/farmacologia , Bainha de Mielina/efeitos dos fármacos , Proteínas de Neurofilamentos/metabolismo , Fármacos Neuroprotetores/metabolismo , Fragmentos de Peptídeos/metabolismo , Ratos Wistar
2.
J Neurosci Res ; 92(2): 243-53, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24327347

RESUMO

During multiple sclerosis (MS), the main axon cystoskeleton proteins, neurofilaments (NF), are altered, and their release into the cerebrospinal fluid correlates with disease severity. The role of NF in the extraaxonal location is unknown. Therefore, we tested whether synthetic peptides corresponding to the tubulin-binding site (TBS) sequence identified on light NF chain (NFL-TBS.40-63) and keratin (KER-TBS.1-24), which could be released during MS, modulate remyelination in vitro. Biotinylated NFL-TBS.40-63, NFL-Scramble2, and KER-TBS.1-54 (1-100 µM, 24 hr) were added to rat oligodendrocyte (OL) and astrocyte (AS) cultures, grown in chemically defined medium. Proliferation and differentiation were characterized by using specific antibodies (A2B5, CNP, MBP, GFAP) and compared with untreated cultures. Lysophosphatidyl choline (LPC; 2 × 10(-5) M) was used to induce OL death and to test the effects of TBS peptides under these conditions. NFL-TBS.40-63 significantly increased OL differentiation and maturation, with more CNP(+) and MBP(+) cells characterized by numerous ramified processes, along with myelin balls. When OL were challenged with LPC, concomitant treatment with NFL-TBS.40-63 rescued more than 50% of OL compared with cultures treated with LPC only. Proliferation of OL progenitors was not affected, nor were AS proliferation and differentiation. NFL-TBS.40-63 peptide induces specific effects in vitro, increasing OL differentiation and maturation without altering AS fate. In addition, it partially protects OL from demyelinating injury. Thus release of NFL-TBS.40-63 caused by axonal damage in vivo could improve repair through increased OL differentiation, which is a prerequisite for remyelination.


Assuntos
Diferenciação Celular/efeitos dos fármacos , Doenças Desmielinizantes/metabolismo , Proteínas de Neurofilamentos/farmacologia , Oligodendroglia/citologia , Oligodendroglia/efeitos dos fármacos , Fragmentos de Peptídeos/farmacologia , Animais , Astrócitos , Técnicas de Cocultura , Imuno-Histoquímica , Lisofosfatidilcolinas/toxicidade , Oligodendroglia/metabolismo , Ratos , Ratos Wistar
3.
Neurochem Int ; 62(3): 306-13, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23279736

RESUMO

Neurofilaments (NF) are detected in the cerebrospinal fluid of multiple sclerosis (MS) patients, and their concentration correlates with disease severity. We recently demonstrated that NF and co-isolated proteins increase the proliferation and differentiation of oligodendrocytes (OL) in vitro. If these proteins are released in the extracellular environment in MS, they might then regulate remyelination by OL. To test this hypothesis we took advantage of a paradigm of OL toxic injury using lysophosphatidyl choline (LPC), which decreases proliferation and differentiation of surviving cells, and destroys myelin-like membranes. In OL cultures that have been treated with LPC, NF fractions as well as tubulin (TUB) significantly improved recovery: the number of OL progenitors (OLP, A2B5+ cells) increased by 100% and their proliferation by 200%, whereas differentiated (CNP+) and mature (MBP+) cells increased by 150% compared to cultures treated with LPC alone. When added at the time of LPC treatment, NF and TUB protected OL from LPC toxicity; they increased OLP by 90%, as well as the number of CNP+ and MBP+ OL by 65-110%, respectively, compared to cultures treated only with LPC. These effects were specific since irrelevant proteins (actin, skin proteins) were ineffective. This demonstrates that NF and TUB protect OL and increase OLP proliferation, as well as their survival, when challenged with LPC, without delaying differentiation and maturation in vitro. Thus, NF and TUB delivered following axonal damage in MS could participate in the regulation of remyelination through this process.


Assuntos
Axônios , Diferenciação Celular , Proliferação de Células , Sobrevivência Celular , Proteínas do Tecido Nervoso/metabolismo , Oligodendroglia/efeitos dos fármacos , Animais , Imuno-Histoquímica , Técnicas In Vitro , Oligodendroglia/citologia , Oligodendroglia/metabolismo , Ratos , Ratos Wistar
4.
Neurochem Int ; 60(1): 78-90, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22080155

RESUMO

In multiple sclerosis (MS) remyelination by oligodendrocytes (OL) is incomplete, and it is associated with a decrease in axonal neurofilaments (NF) and tubulin (TUB). To determine whether these proteins could participate directly in MS remyelination failure, or indirectly through proteins that are co-associated, we have analysed their effects in pure OL cultures. Rat brain NF fractions, recovered by successive centrifugations increase either OL progenitor (OLP) proliferation (2nd pellet, P2), or only their maturation (P5), whereas albumin, liver and skin proteins, as well as recombinant GFAP or purified actin were ineffective. NF (P2) copurify mainly with TUB, as well as with other proteins, like MAPs, Tau, spectrin ß2, and synapsin 2. These purified, or recombinant, proteins increased OLP proliferation without delaying their maturation, and appeared responsible for the proliferation observed with P2 fractions. Among putative signaling pathways mediating these effects Fyn kinase was not involved. Whereas NF did not alter the growth of cultured astrocytes, the NF associated proteins enhanced their proliferation. This suggests that NF and their associated proteins exert specific effects on OL development, broadening the field of axon-oligodendrocyte interactions. In case of axon damage in vivo, extracellular release of such axonal proteins could regulate remyelination and astrocytic gliosis.


Assuntos
Axônios/fisiologia , Diferenciação Celular , Proteínas de Neurofilamentos/farmacologia , Oligodendroglia/citologia , Animais , Astrócitos/citologia , Astrócitos/metabolismo , Axônios/química , Diferenciação Celular/efeitos dos fármacos , Células Cultivadas , Proteínas do Citoesqueleto/farmacologia , Oligodendroglia/efeitos dos fármacos , Oligodendroglia/metabolismo , Ratos , Ratos Sprague-Dawley
5.
Muscle Nerve ; 44(3): 332-9, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21996792

RESUMO

INTRODUCTION: To detail the extent and pattern of axon cytoskeleton alterations in chronic inflammatory demyelinating polyneuropathy (CIDP). METHODS: Nerve biopsies from 7 cases of CIDP, including 4 cases with severe fiber loss, were compared with 5 controls by morphometric transmission electron microscopy (TEM). RESULTS: Despite demyelination of single fibers, myelin ultrastructure was otherwise normal. Contrary to immunolabeling, TEM revealed a decrease in neurofilament (NF) density in every case, although there were pronounced variations among fibers even in the same sample. The NF decrease reached the same extent in large- and small-diameter fibers. It was observed in normally myelinated fibers, suggesting they were demyelinated at a distance from the section. Minimal inter-NF distance increased roughly inversely to NF density. Microtubules increased in 3 cases previously characterized by increased growth-associated protein (GAP-43) immunolabeling. CONCLUSION: These data demonstrate the severity and constancy of axonal lesions, and especially of NF, in residual fibers in our cases of CIDP.


Assuntos
Axônios/ultraestrutura , Citoesqueleto/ultraestrutura , Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/patologia , Idoso , Axônios/patologia , Biópsia , Estudos de Casos e Controles , Feminino , Proteína GAP-43/metabolismo , Humanos , Masculino , Microtúbulos/ultraestrutura , Pessoa de Meia-Idade , Bainha de Mielina/ultraestrutura , Neurofibrilas/ultraestrutura , Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/metabolismo , Índice de Gravidade de Doença
6.
Glia ; 49(4): 555-66, 2005 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15578728

RESUMO

In multiple sclerosis, relapses occur and remyelination is incomplete, whereas one demyelinating lesion induced by lysophosphatidyl choline (LPC) in rats is completely remyelinated; this process is accelerated by platelet-derived growth factor (PDGF) (Allamargot et al.: Brain Res 918:28-39,2001) and neurotrophin-3 (NT-3) (Jean et al.: Brain Res 972:110-118,2003). Similarly, oligodendrocyte (OL) progenitors might not be depleted by two to three episodes of toxic demyelination (Penderis et al.: Brain 126:1382-1391,2003); nevertheless this does not allow conclusions about the fate of resident cells (mature OL). As myelinated fibers per OL are constantly decreased in chronic MS plaques (Fressinaud and Jean: J Neurochem 85(suppl):100, 2003), this suggests that OL decreased capability to synthesize new myelin membranes could result from successive relapses, impairing thereby remyelination. Thus, we have determined the consequences of multiple versus unique (Fressinaud and Vallat: J Neurosci Res 38:202-213, 1994) LPC treatments on newborn rat brain pure OL cultures, as well as the putative pro-remyelinating effects of PDGF and of NT-3 in these conditions. Split (0.5. 0(-5) M, 6 h x 4) and multiple (2.10(-5) M, 24 h x 2) LPC doses induced more cell loss than a unique treatment (2 x 10(-5) M, 24 h) and there was no recovery. OL progenitors (A2B5+ cells) and differentiated (CNP+) OL were drastically decreased. Moreover, mature (MBP+) OL disappeared from these cultures, indicating that mature OL are also vulnerable to multiple insults. PDGF, as well as NT-3, induced at least partial recovery, and enhanced OL progenitor proliferation. In cultures treated with either of these growth factors, mature OL represented one-fourth of cells and extended numerous ramified processes and putative myelin balls.


Assuntos
Esclerose Múltipla Recidivante-Remitente/metabolismo , Bainha de Mielina/metabolismo , Neurotrofina 3/farmacologia , Oligodendroglia/metabolismo , Fator de Crescimento Derivado de Plaquetas/farmacologia , Células-Tronco/metabolismo , Animais , Animais Recém-Nascidos , Morte Celular/efeitos dos fármacos , Morte Celular/fisiologia , Diferenciação Celular/efeitos dos fármacos , Diferenciação Celular/fisiologia , Células Cultivadas , Relação Dose-Resposta a Droga , Regulação para Baixo/efeitos dos fármacos , Regulação para Baixo/fisiologia , Esquema de Medicação , Mediadores da Inflamação/toxicidade , Lisofosfatidilcolinas/toxicidade , Bainha de Mielina/efeitos dos fármacos , Bainha de Mielina/patologia , Regeneração Nervosa/efeitos dos fármacos , Oligodendroglia/efeitos dos fármacos , Oligodendroglia/patologia , Ratos , Ratos Wistar , Recuperação de Função Fisiológica/efeitos dos fármacos , Recuperação de Função Fisiológica/fisiologia , Células-Tronco/efeitos dos fármacos , Células-Tronco/patologia
7.
J Neurosci Res ; 73(1): 54-60, 2003 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-12815708

RESUMO

Harmonious functioning of the nervous system depends on neuron-glia interactions, particularly between the axons and their myelinating cells, i.e., oligodendrocytes (OL) in the central nervous system (CNS). In human demyelinating diseases such as multiple sclerosis (MS), demyelination may be associated with axonal damage, but alterations of the axonal cytoskeleton, which is composed mainly of neurofilaments (NF) and microtubules, are largely unknown, as are the consequences on remyelination. In a model of demyelination induced by lysophosphatidylcholine (LPC), we have shown that demyelination was correlated with a decrease in NF immunolabelling, and that these axonal abnormalities were reduced by platelet-derived growth factor (PDGF)-enhanced remyelination in adult rats. We have analysed the spontaneous remyelination after LPC stereotaxic injection in the CNS of transgenic NFH-lacZ mice, which present axonal atrophy caused by abnormal distribution of NF, associated with hypermyelination in the PNS, and normal myelin thickness in the CNS. Axonal atrophy in the CNS of NFH-lacZ mice was confirmed, but it was not worsened by demyelination. On the contrary, demyelination induced axonal atrophy in wild-type mice, demonstrating that NF are essential for axonal calibre determination. Moreover, an efficient spontaneous remyelination occurred in NFH-lacZ as well as in wild-type mice, indicating that the NF are not necessary for CNS remyelination. These findings point out that NF modifications observed in MS may not be responsible for the lack of remyelination in this disease.


Assuntos
Doenças Desmielinizantes/patologia , Regeneração Nervosa/fisiologia , Proteínas de Neurofilamentos/genética , Animais , Atrofia , Doenças Desmielinizantes/induzido quimicamente , Óperon Lac , Lisofosfatidilcolinas , Masculino , Camundongos , Camundongos Transgênicos , Esclerose Múltipla/patologia , Fibras Nervosas Mielinizadas/patologia , Remissão Espontânea
8.
Acta Neuropathol ; 105(5): 477-83, 2003 May.
Artigo em Inglês | MEDLINE | ID: mdl-12677448

RESUMO

In an attempt to approach the mechanisms underlying axonopathies of unknown etiology, we have studied by immunocytochemistry the fate of several growth factors in eight of such cases that we had previously analyzed by morphometry and which were characterized by a decrease in neurofilaments and an increase in beta tubulin immunostaining. Here we establish that, contrary to beta tubulin, growth-associated protein43 (GAP-43) immunolabeling is not up-regulated in theses cases, correlating well with the failure of regeneration. Neurotrophin-3 (NT-3) and its receptor TrkC were not modified compared to controls (five cases). On the contrary, we observed in all cases a pronounced decrease in the number of fibers labeled for nerve growth factor (NGF) and insulin-like growth factor I (IGF-I), which were both approximately half of control values. This decrease could not be ascribed to the reduction in fiber density since it was also present in cases without fiber loss (isolated large fiber atrophy). The fact that only around 50% of fibers were stained, versus all fibers in controls, probably accounted for this decrease. It contrasted also with the normality of NGF and IGF-I immunolabeling in six cases of chronic inflammatory demyelinating neuropathy that were investigated in parallel. These results differ from those reported in experimental diabetic neuropathy, during which NT-3 is also decreased. A deficient supply of specific growth factors delivered by neuronal targets may be responsible for these neuropathies and their associated axonal cytoskeleton abnormalities.


Assuntos
Axônios/metabolismo , Axônios/patologia , Fator de Crescimento Insulin-Like I/metabolismo , Fator de Crescimento Neural/metabolismo , Doenças do Sistema Nervoso Periférico/metabolismo , Adulto , Idoso , Atrofia/metabolismo , Atrofia/patologia , Feminino , Humanos , Imuno-Histoquímica/métodos , Masculino , Pessoa de Meia-Idade , Nervo Musculocutâneo/metabolismo , Doenças do Sistema Nervoso Periférico/patologia
9.
Brain Res ; 972(1-2): 110-8, 2003 May 16.
Artigo em Inglês | MEDLINE | ID: mdl-12711083

RESUMO

In human central nervous system (CNS) demyelinating diseases, spontaneous remyelination is often incomplete. Therefore, we have tested whether neutrotrophin-3 (NT-3) accelerates CNS myelin repair after a chemically-induced demyelination. One group of adult rats was injected in the corpus callosum (CC) with 1 microl of 1% lysophosphatidylcholine (LPC) and 1 microl of NT-3 (1 microg/microl), and 15 days after injury (D15) remyelination was compared to control rats (receiving 1 microl of LPC+1 microl of vehicle buffer of NT-3). The demyelinated volume decreased by 56% in NT-3-treated rats at D15, and immunohistochemistry showed an increase in mature MBP(+) oligodendrocytes (OL) (+66%) in treated animals (whereas less mature (CNP(+)) OL were unchanged). Since less than 3% axons degenerate in this model, and as astrocytic gliosis was not modified, these data suggest that NT-3 acts directly on cells of the OL lineage to enhance remyelination in vivo.


Assuntos
Doenças Desmielinizantes/patologia , Regeneração Nervosa/fisiologia , Neurotrofina 3/farmacologia , Oligodendroglia/efeitos dos fármacos , 2',3'-Nucleotídeo Cíclico Fosfodiesterases/metabolismo , Animais , Bromodesoxiuridina/metabolismo , Doenças do Sistema Nervoso Central/patologia , Doenças do Sistema Nervoso Central/fisiopatologia , Corpo Caloso/efeitos dos fármacos , Corpo Caloso/patologia , Doenças Desmielinizantes/induzido quimicamente , Doenças Desmielinizantes/fisiopatologia , Modelos Animais de Doenças , Proteína Glial Fibrilar Ácida/metabolismo , Imuno-Histoquímica , Lisofosfatidilcolinas/toxicidade , Masculino , Proteína Básica da Mielina/metabolismo , Oligodendroglia/metabolismo , Ratos , Ratos Wistar , Células-Tronco/metabolismo , Fatores de Tempo
10.
Neuroreport ; 13(5): 627-31, 2002 Apr 16.
Artigo em Inglês | MEDLINE | ID: mdl-11973459

RESUMO

In multiple sclerosis (MS), demyelination is often accompanied by axonal lesions, which largely account for patient disability. We therefore studied the consequences of demyelination induced by lysophosphatidylcholine (LPC) on the axonal cytoskeleton, particularly neurofilaments (NF) and tubulin, in the adult rat corpus callosum. Immunocytochemistry showed that NF immunolabelled fibres decreased by 49% in the LPC injured area at day 15. Since it has been previously demonstrated that PDGF improves remyelination, we performed a comparative study between LPC controls and PDGF-treated (1 microg) animals. In these later animals, immunolabelling for NFL and NFM (NFH subunit excepted) was increased by 142 and 63%, respectively, indicating reduction of axonal abnormalities. These results extend the potential therapeutic role of PDGF in MS.


Assuntos
Axônios/efeitos dos fármacos , Corpo Caloso/efeitos dos fármacos , Doenças Desmielinizantes/induzido quimicamente , Lisofosfatidilcolinas/efeitos adversos , Bainha de Mielina/efeitos dos fármacos , Fator de Crescimento Derivado de Plaquetas/farmacologia , Animais , Axônios/metabolismo , Corpo Caloso/metabolismo , Doenças Desmielinizantes/tratamento farmacológico , Masculino , Bainha de Mielina/metabolismo , Proteínas de Neurofilamentos/metabolismo , Fator de Crescimento Derivado de Plaquetas/uso terapêutico , Ratos , Ratos Wistar , Técnicas Estereotáxicas
11.
J Neurol Sci ; 196(1-2): 53-61, 2002 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-11959157

RESUMO

To determine if specific axonal cytoskeleton abnormalities could be demonstrated in axonopathies without aetiology, nerve biopsies from five controls and nine cases were analyzed by morphometry and immunocytochemistry with anti-neurofilament (NF, subunits L, M, H) and anti-beta tubulin (TUB) antibodies. Morphometry revealed either large fiber atrophy (decrease in large fiber density with increased density in small fibers), degeneration of large fibers (decrease in large fiber density and in total density of fibers) or of all diameter fibers. NF immunostaining density decreased (by 21-89%) only in cases with fiber loss, in parallel to myelinated fiber density as determined by morphometry. On the contrary, the density of fibers labelled for TUB increased significantly in all except two cases by 52-102% over controls. Nevertheless, in these two cases--with a severe loss of fibers--as well as in other cases, the ratio of the density of fibers labelled for TUB and NFL (TUB/NFL) increased by 48-404%. Thus, the total density of myelinated fibers was always inversely correlated with the TUB/NFL ratio. Similar abnormalities have been described only after axotomy; our cases could thus be compared to <>.


Assuntos
Axônios/metabolismo , Citoesqueleto/metabolismo , Degeneração Neural/metabolismo , Nervos Periféricos/metabolismo , Doenças do Sistema Nervoso Periférico/metabolismo , Adulto , Idoso , Atrofia/metabolismo , Atrofia/patologia , Atrofia/fisiopatologia , Axônios/patologia , Contagem de Células , Citoesqueleto/patologia , Feminino , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , Degeneração Neural/patologia , Degeneração Neural/fisiopatologia , Fibras Nervosas/metabolismo , Fibras Nervosas/patologia , Fibras Nervosas Mielinizadas/metabolismo , Fibras Nervosas Mielinizadas/patologia , Condução Nervosa/fisiologia , Proteínas de Neurofilamentos/metabolismo , Nervos Periféricos/patologia , Nervos Periféricos/fisiopatologia , Doenças do Sistema Nervoso Periférico/patologia , Doenças do Sistema Nervoso Periférico/fisiopatologia , Tubulina (Proteína)/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...